Ahmad Masri

发表

Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond.

I. Olivotto, D. Jacoby, C. Morelli, 2022, European journal of internal medicine.

Chest Pain and Inflammation: A Story Where Hickam's Dictum Prevailed.

B. Nazer, F. Zahr, H. Golwala, 2022, The American journal of medicine.

Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer

Dayna Carlson, Jack J. Chen, Ahmad Masri, 2022, Journal of the American Heart Association.

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

I. Olivotto, Ahmad Masri, 2022, Journal of the American Heart Association.

A New Dawn in HCM: Rise of the RCTs.

Ahmad Masri, 2021, Journal of the American College of Cardiology.

Liver‐directed drugs for transthyretin‐mediated amyloidosis

M. Maurer, B. Baker, M. Fontana, 2022, Journal of the peripheral nervous system : JPNS.

Genetic Cardiomyopathy Masquerading as Cardiac Sarcoidosis.

S. A. Camacho, B. Nazer, Ahmad Masri, 2023, Journal of the American College of Cardiology.

Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women.

B. Nazer, Morris M. Kim, Yuanzi Zhao, 2022, International journal of cardiology.

Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics

A. Altibi, Yuanzi Zhao, Ahmad Masri, 2023, Current Cardiology Reports.

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.

C. Kramer, H. Watkins, T. Wong, 2023, Journal of the American College of Cardiology.

Imaging cardiac hypertrophy in hypertrophic cardiomyopathy and its differential diagnosis

J. Hodovan, Ahmad Masri, L. Rashdan, 2023, Current opinion in cardiology.

Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption

M. Wheeler, M. Maurer, I. Olivotto, 2023, JAMA cardiology.

Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy

E. Stecker, B. Nazer, Ahmad Masri, 2023, Communications medicine.

Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy

Miriam R. Elman, J. Cigarroa, B. Nazer, 2023, Journal of the American Heart Association.

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.

T. Wong, M. Maron, I. Olivotto, 2023, Journal of cardiac failure.

AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (REDWOOD-HCM COHORT 4)

T. Abraham, H. Watkins, T. Wong, 2023, Journal of the American College of Cardiology.

LONG-TERM EFFICACY AND SAFETY OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

T. Abraham, H. Watkins, M. Maron, 2023, Journal of the American College of Cardiology.

EFFICACY AND SAFETY OF AFICAMTEN AND DISOPYRAMIDE COADMINISTRATION IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: RESULTS FROM REDWOOD-HCM COHORT 3

S. Solomon, T. Abraham, H. Watkins, 2022, Journal of the American College of Cardiology.

LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY

S. Lester, A. Sehnert, G. Balaratnam, 2023, Journal of the American College of Cardiology.

Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.

B. Nazer, Morris M. Kim, C. Kolseth, 2023, Journal of the American Heart Association.

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Karla P. Zepeda, Hansie M Mathelier, J. Felius, 2023, Neurology and Therapy.